LFCRLifecore Biomedical, Inc.

$267M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$38M+48.5% YoY

Gross Profit

$17M45.6% margin

Operating Income

$2M5.7% margin

Net Income

-$7M-18.7% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+6.1%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$254M

Total Liabilities

$243M

Stockholders' Equity

$11M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$26M	+48.5%
Gross Profit	$17M	$8M	+105.3%
Operating Income	$2M	-$1M	+274.1%
Net Income	-$7M	-$36M	+80.1%

LFCR Q4 2024 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena